RPL36B Antibody

What is RPL36 and what are the basic applications of RPL36 antibody?

RPL36, also known as 60S ribosomal protein L36, is a 105 amino acid protein that functions as a component of the large ribosomal subunit. The RPL36 antibody is primarily used in Western Blot (WB), Immunofluorescence (IF)/Immunocytochemistry (ICC), and ELISA applications. The antibody shows reactivity with human, mouse, and rat samples, making it versatile for cross-species research applications . Beyond basic protein detection, RPL36 antibody can be particularly valuable in studying hepatocarcinogenesis, as RPL36 may be involved in the early stages of this process and can potentially serve as an independent prognostic marker for resected hepatocellular carcinoma (HCC) .

What is the recommended dilution range for RPL36 antibody in different applications?

For Western Blot applications, the recommended dilution range is 1:500-1:2,000, though some specific antibodies like the Proteintech 15145-1-AP recommend a narrower range of 1:500-1:1000 . For Immunohistochemistry (IHC), use a dilution range of 1:50-1:200 . For Immunofluorescence (IF)/Immunocytochemistry (ICC) applications, the optimal dilution range is generally 1:50-1:200, though specific products like Proteintech's antibody suggest 1:200-1:800 . It's important to note that optimal dilutions should be determined empirically for each experimental system, as the ideal concentration may be sample-dependent .

What are the optimal storage conditions for maintaining RPL36 antibody activity?

RPL36 antibodies should be stored at -20°C for long-term stability. Most commercial preparations remain stable for one year after shipment when stored properly . The antibody is typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 to maintain stability . For antibodies stored at -20°C, aliquoting is generally unnecessary, which simplifies laboratory handling procedures. Some preparations (particularly those in 20μl sizes) may contain 0.1% BSA as a stabilizer . Always avoid repeated freeze-thaw cycles as this can compromise antibody performance.

How should I validate the specificity of RPL36 antibody in my experimental system?

Validation of RPL36 antibody specificity requires a multi-faceted approach. Begin with Western blot analysis to confirm detection of the correct molecular weight band (12-14 kDa for RPL36) . Include both positive control cell lines known to express RPL36 (such as PC-12, BxPC-3, HeLa, HepG2, or NIH/3T3 cells) and negative controls where RPL36 expression is knocked down or absent . For immunofluorescence applications, co-localization studies with known ribosomal markers can provide additional validation. Most importantly, verify antibody specificity in your particular experimental context by confirming that the observed band patterns match the expected molecular weight and that signal intensity correlates with expected expression levels across different samples. Alternative antibodies recognizing different epitopes of RPL36 can also be used to confirm findings.

What are the technical considerations for detecting phosphorylated forms of RPL36 or its alternative reading frame products?

Detecting phosphorylated forms of RPL36 or its alternative reading frame products (such as alt-RPL36) requires special technical considerations. For alt-RPL36, which can exist in phosphorylated states, Phos-tag SDS-PAGE followed by western blotting provides excellent resolution of phosphorylated variants . Phosphatase treatment of samples can confirm the presence of phosphorylated forms by eliminating upper bands in western blots . For identifying specific phosphorylation sites, LC-MS/MS analysis of immunopurified, digested protein is the gold standard method . When working with alt-RPL36, be aware that it has four potential phosphoserine residues (S19, S22, S140, and S142) that can be phosphorylated and may affect protein function . Mutational analysis (changing serine to alanine) combined with Phos-tag SDS-PAGE can further confirm specific phosphorylation sites and their interdependencies.

How can I optimize immunofluorescence protocols to study the subcellular localization of RPL36 and its alternative reading frame proteins?

To optimize immunofluorescence protocols for RPL36 and alt-RPL36 subcellular localization studies, consider the following methodological approach. First, establish proper fixation conditions—4% paraformaldehyde for 15 minutes at room temperature works well for preserving RPL36 structures. For membrane-associated variants like alt-RPL36, include a gentle permeabilization step using 0.1-0.2% Triton X-100 for 5-10 minutes . When studying alt-RPL36, co-staining with endoplasmic reticulum markers such as Grp94 is essential, as alt-RPL36 partially localizes to the ER . For live-cell imaging, consider genetic code expansion-mediated labeling techniques using unnatural amino acids like bicyclononyne-lysine (BCNK) and subsequent derivatization with tetrazine-silicon rhodamine conjugates . Use high-resolution confocal microscopy with z-stack acquisition to properly capture the three-dimensional distribution of these proteins. When confirming endogenous expression, knock-in approaches with epitope tags (such as 3xGFP11-FLAG) can provide specificity while minimizing disruption to normal protein function .

How does alt-RPL36 influence the PI3K-AKT-mTOR signaling pathway and what are the implications for ribosomal biology research?

Alt-RPL36, an alternative reading frame product of the RPL36 transcript variant 2, has been demonstrated to downregulate the PI3K-AKT-mTOR signaling pathway. Knockout studies reveal that removing alt-RPL36 increases plasma membrane PI(4,5)P2 levels, upregulates PI3K-AKT-mTOR signaling, and increases cell size . This indicates that alt-RPL36 functions as a negative regulator of this critical growth signaling pathway.

The discovery has significant implications for ribosomal biology research. First, it reveals a novel regulatory mechanism where alternative reading frame products of ribosomal protein genes can influence signaling pathways independent of their canonical counterparts. Second, it suggests that ribosomal proteins may have extra-ribosomal functions that extend beyond protein synthesis. For researchers studying RPL36, it becomes essential to distinguish between the canonical protein's effects and those of its alternative reading frame product. Methodologically, this necessitates specific antibodies or genetic approaches that can selectively target each protein variant. Experiments examining ribosomal function should consider the potential confounding effects of alt-RPL36 on cellular signaling, particularly when manipulating RPL36 expression.

What approaches can be used to distinguish between the functions of canonical RPL36 and alt-RPL36 in experimental systems?

Distinguishing between canonical RPL36 and alt-RPL36 functions requires sophisticated experimental approaches due to their overlapping genomic origins but distinct amino acid sequences.

One effective strategy is CRISPR-Cas9 genome editing to create specific mutations that affect only one protein while preserving the other. For example, introducing premature stop codons in the alt-RPL36 reading frame that don't affect the RPL36 coding sequence would selectively eliminate alt-RPL36 expression . Alternatively, epitope tagging of each protein individually through knock-in approaches allows for protein-specific immunoprecipitation and functional studies.

RNA interference can be designed to target unique regions of each transcript variant, though this requires careful validation to ensure specificity. For functional studies, rescue experiments are critical—phenotypes observed after knocking down both proteins should be rescued by expressing either RPL36 or alt-RPL36 independently to determine their distinct contributions.

Mass spectrometry-based approaches can identify interacting partners specific to each protein, providing insights into their separate functional networks . Finally, custom antibodies raised against unique peptide sequences of each protein enable specific detection in various applications, though extensive validation is necessary to confirm their selectivity.

What are the methodological considerations for studying RPL36 phosphorylation dynamics in different cellular contexts?

Studying RPL36 phosphorylation dynamics across different cellular contexts requires careful methodological considerations. First, establish a baseline phosphorylation profile using Phos-tag SDS-PAGE combined with western blotting in your cellular system of interest . This technique physically separates phosphorylated forms of the protein based on their migration rates.

To assess dynamic changes, implement time-course experiments following relevant stimuli (growth factors, stress conditions, cell cycle synchronization) with multiple time points to capture transient phosphorylation events. Phospho-specific antibodies, if available, allow for direct monitoring of specific phosphosites, though these may need to be custom-developed for RPL36.

For site-specific analysis, employ phosphosite mutants (S→A to prevent phosphorylation or S→D/E to mimic constitutive phosphorylation) to determine the functional significance of individual phosphorylation events . Mass spectrometry-based phosphoproteomics with stable isotope labeling (SILAC or TMT) enables quantitative comparison of phosphorylation states across different cellular conditions.

When studying alt-RPL36, be particularly attentive to the interdependency of phosphorylation events, as demonstrated by the requirement of S22 phosphorylation for subsequent S19 phosphorylation . Kinase inhibitor screens can help identify the specific kinases responsible for RPL36 phosphorylation under different cellular conditions. Finally, subcellular fractionation prior to phosphorylation analysis can reveal compartment-specific phosphorylation patterns, particularly relevant for alt-RPL36 which shows partial ER localization .

How can I resolve multiple band patterns in Western blots when using RPL36 antibodies?

When encountering multiple bands in Western blots using RPL36 antibodies, systematic troubleshooting is essential. First, verify that one band appears at the expected molecular weight of 12-14 kDa for canonical RPL36 . Additional bands may represent post-translational modifications, alternative splice variants, or alternative reading frame products like alt-RPL36 .

To distinguish between these possibilities, treat samples with phosphatase prior to Western blotting—if higher molecular weight bands disappear, they likely represent phosphorylated forms . For suspected alternative reading frame products, design experiments using constructs that selectively express either canonical RPL36 or alt-RPL36 as positive controls.

Using gradient gels (4-20%) can improve resolution of closely migrating bands. Sample preparation methods also matter—different lysis buffers may preserve or disrupt certain protein modifications or complexes. For cross-reactivity concerns, try multiple antibodies targeting different epitopes of RPL36—consistent bands across different antibodies increase confidence in specificity.

For alt-RPL36 specifically, note that it typically produces two bands when detected with appropriate antibodies: a major lower-mobility band and a fainter higher-mobility band, with the upper band representing phosphorylated forms . Finally, incorporate appropriate positive controls (cell lines known to express RPL36) and negative controls (RPL36 knockdown samples) to validate band specificity.

What control experiments are necessary to validate findings in RPL36 knockdown or knockout studies?

Validating findings in RPL36 knockdown or knockout studies requires rigorous control experiments. First, verify knockdown/knockout efficiency at both mRNA (RT-qPCR) and protein levels (Western blot) using validated primers and antibodies . Include multiple siRNA/shRNA sequences or CRISPR guide RNAs targeting different regions of RPL36 to minimize off-target effects.

For functional validation, employ cell viability assays, as ribosomal proteins are often essential. Time-course experiments can differentiate between primary effects and secondary adaptations. When investigating specific pathways like PI3K-AKT-mTOR that are known to be affected by alt-RPL36, confirm pathway changes using multiple readouts (phospho-specific Western blots, reporter assays, downstream target expression) .

If studying subcellular localization, complement imaging data with biochemical fractionation. Finally, perform RNA-seq or proteomics analysis to identify global changes and potential compensatory mechanisms activated upon RPL36 manipulation, as ribosomal protein deficiencies often trigger complex cellular responses.

How should I interpret conflicting data between different detection methods when studying RPL36 localization?

When faced with conflicting data between different detection methods for RPL36 localization, systematic analysis is required. First, evaluate the inherent limitations of each technique: immunofluorescence provides spatial resolution but may suffer from antibody cross-reactivity or fixation artifacts; biochemical fractionation offers higher sensitivity but may introduce contamination between fractions; live-cell imaging with genetic tags provides dynamic information but tag addition might alter protein behavior .

To resolve discrepancies, begin by validating reagents—test antibody specificity using RPL36 knockdown controls and multiple antibodies targeting different epitopes. Consider fixation artifacts by comparing different fixation methods (paraformaldehyde, methanol, glutaraldehyde) which may differentially preserve protein localization.

For epitope-tagged RPL36 constructs, verify that both N- and C-terminal tags yield consistent results, as tag position may affect localization. Compare overexpression systems with endogenous detection methods (like knock-in cell lines with 3xGFP11-FLAG tags) to identify potential artifacts from non-physiological expression levels .

Advanced imaging techniques like super-resolution microscopy may resolve apparent conflicts by providing higher spatial resolution. Importantly, consider the biological context—RPL36 and especially alt-RPL36 may shuttle between compartments depending on cellular state . Time-course experiments following cellular perturbations (stress, cell cycle changes) can reveal dynamic localization patterns and reconcile seemingly contradictory static observations.

How can machine learning approaches improve antibody-antigen binding prediction for RPL36 and other ribosomal proteins?

Machine learning approaches offer significant potential for improving antibody-antigen binding prediction for RPL36 and other ribosomal proteins. Recent research has demonstrated that library-on-library approaches, where many antigens are probed against many antibodies, can generate valuable datasets for training predictive models . These approaches are particularly relevant for ribosomal proteins due to their highly conserved nature and potential cross-reactivity.

For developing RPL36-specific antibodies with improved specificity, active learning strategies can significantly reduce experimental costs. In particular, models that incorporate out-of-distribution prediction capabilities have shown promise in antibody development pipelines . Starting with a small labeled subset of binding data and iteratively expanding this dataset using strategic selection algorithms can reduce the number of required antigen mutant variants by up to 35% .

Methodologically, researchers should consider implementing ensemble models that combine sequence-based features with structural information when available. For RPL36 specifically, models should account for its unique structural features and distinguish it from closely related ribosomal proteins. When developing new RPL36 antibodies, researchers can leverage these computational predictions to prioritize candidate antibodies for experimental validation, focusing on those predicted to have high specificity for RPL36 versus its alternative reading frame product or other ribosomal proteins.

What are the implications of alt-RPL36 discovery for understanding the broader landscape of alternative reading frame proteins in ribosomal biology?

The discovery of alt-RPL36 has profound implications for our understanding of ribosomal biology and alternative reading frame proteins. Alt-RPL36 is translated from an alternative reading frame of human RPL36 transcript variant 2, producing a protein with a completely different amino acid sequence despite sharing genomic space with canonical RPL36 . This finding suggests that the functional complexity of ribosomal protein genes may be vastly underestimated.

Methodologically, researchers should now consider implementing ribosome profiling and proteogenomic approaches to identify other potential alternative reading frame products from ribosomal protein genes. These techniques can detect translation occurring in non-canonical reading frames and validate their expression at the protein level. For any identified candidates, knock-in tagging strategies similar to those used for alt-RPL36 (3xGFP11-FLAG tagging) can confirm endogenous expression .

The functional divergence between RPL36 and alt-RPL36—with the latter regulating PI3K-AKT-mTOR signaling—suggests that alternative reading frame products may serve regulatory roles distinct from their canonical counterparts . This challenges the traditional view of ribosomal proteins as primarily structural components of ribosomes and opens new research directions exploring their extra-ribosomal functions.

When studying ribosomal protein genes, researchers should now routinely examine alternative open reading frames for potential coding capacity and functional significance. This expanded perspective may help explain previously contradictory findings in ribosomal protein research and reveal new therapeutic targets in diseases associated with ribosomal dysfunction.

How might phosphorylation patterns of RPL36 and alt-RPL36 serve as biomarkers in cancer and other diseases?

The distinct phosphorylation patterns of RPL36 and particularly alt-RPL36 offer promising potential as disease biomarkers. Alt-RPL36 exhibits four identified phosphoserine residues (S19, S22, S140, and S142) with evidence of interdependent phosphorylation events, such as S22 phosphorylation being required for subsequent S19 phosphorylation . These specific patterns may serve as unique molecular signatures in disease states.

For cancer applications, the involvement of RPL36 in early-stage hepatocarcinogenesis already suggests its potential as a prognostic marker for hepatocellular carcinoma . Methodologically, researchers should develop quantitative assays that can detect not only total RPL36/alt-RPL36 levels but also their specific phosphorylation states. Phos-tag SDS-PAGE combined with western blotting provides a practical approach for research settings , while developing phospho-specific antibodies would enable more accessible clinical applications.

To establish these proteins as biomarkers, researchers should conduct comparative phosphoproteomic studies across multiple cancer types versus matched normal tissues, correlating phosphorylation patterns with clinical outcomes. The connection between alt-RPL36 and PI3K-AKT-mTOR signaling—a pathway frequently dysregulated in cancer—further strengthens its potential relevance as a biomarker .

Beyond cancer, alterations in ribosomal protein expression and modification have been implicated in neurodegenerative diseases and inflammatory conditions. Longitudinal studies tracking RPL36/alt-RPL36 phosphorylation states during disease progression could establish their utility for early detection or monitoring therapeutic responses. When developing such biomarker applications, researchers should employ multiple detection methods and establish standardized protocols to ensure reproducibility across different laboratories and clinical settings.